Rucaparib (AG-014699): Potent PARP1 Inhibitor for DNA Repair Research

Executive Summary: Rucaparib (AG-014699, PF-01367338) is a highly potent poly (ADP ribose) polymerase 1 (PARP1) inhibitor (Ki = 1.4 nM) [source_type: product_spec, source_link]. It impairs the base excision repair pathway and selectively radiosensitizes PTEN-deficient, ETS fusion-expressing prostate cancer cells [source_type: paper, DOI]. Rucaparib is validated for DNA damage response research and exhibits robust solubility in DMSO (≥21.08 mg/mL) but is insoluble in ethanol and water [product_spec, source]. Cellular disposition studies reveal it is a substrate of the ABCB1 transporter, affecting oral bioavailability and brain penetration [paper, DOI]. APExBIO supplies Rucaparib (A4156) for non-clinical, research use only.

Biological Rationale

Poly (ADP ribose) polymerase 1 (PARP1) is a nuclear enzyme activated by DNA strand breaks. It is central to the base excision repair (BER) pathway, which repairs single-strand DNA breaks to maintain genomic stability [paper, DOI]. Inhibition of PARP1 causes persistent DNA lesions, especially in cells with homologous recombination repair (HRR) deficiencies, leading to synthetic lethality. Tumors with PTEN loss or ETS gene fusion frequently display impaired DNA repair and are selectively vulnerable to PARP1 inhibition [paper, DOI].

Mechanism of Action of Rucaparib (AG-014699, PF-01367338)

Rucaparib is a competitive inhibitor at the NAD⁺ binding site of PARP1, with a measured inhibition constant (Ki) of 1.4 nM [product_spec, source]. Inhibition of PARP1 prevents poly-ADP ribosylation of DNA repair proteins, blocking recruitment of DNA repair complexes to damaged sites. In vitro, Rucaparib exposure leads to accumulation of γ-H2AX and p53BP1 foci, markers of double-strand DNA breaks [paper, DOI]. Cells deficient in HRR (e.g., BRCA1/2, PTEN) or non-homologous end joining (NHEJ) are particularly sensitive. Rucaparib also acts as a radiosensitizer, enhancing the effect of ionizing radiation by preventing DNA repair, particularly in prostate cancer models with PTEN loss and ETS gene fusion [paper, DOI].

Evidence & Benchmarks

• Rucaparib (AG-014699) achieves PARP1 inhibition with a Ki of 1.4 nM at physiological pH and temperature [product_spec, source].
• In PTEN-deficient, ETS fusion-expressing prostate cancer cells, Rucaparib increases radiosensitivity and induces persistent γ-H2AX foci, indicating unresolved DNA double-strand breaks [paper, DOI].
• Rucaparib demonstrates solubility ≥21.08 mg/mL in DMSO at 20–25°C; insoluble in ethanol and water [product_spec, source].
• In vitro, Rucaparib is a substrate for ABCB1, which limits intracellular accumulation in transporter-expressing cells [paper, DOI].
• In vivo, knockout of Abcg2 and Abcb1a/1b in mice increases Rucaparib oral bioavailability and enhances brain penetration [paper, DOI].

This article provides updated mechanistic clarity beyond "Rucaparib (AG-014699): Unveiling PARP1 Inhibition and Mitochondrial Apoptosis" by detailing validated transporter interactions and protocol parameters for experimental use.

For a workflow-focused guide to cell viability and DNA damage response assays using Rucaparib, see "Rucaparib (AG-014699, PF-01367338): Optimizing DNA Damage..."; this article extends by providing updated evidence for transporter influence on compound disposition.

Applications, Limits & Misconceptions

Rucaparib is intended for DNA damage response research, cancer biology experiments, and as a tool for radiosensitization studies, especially in genetically defined cancer models [product_spec, source]. It enables mechanistic dissection of base excision repair and non-homologous end joining (NHEJ) inhibition. The compound is not validated for diagnostic or therapeutic use in humans or animals. Its performance in cells expressing drug efflux transporters (e.g., ABCB1) may be reduced due to active expulsion, requiring consideration in experimental design [paper, DOI].

Common Pitfalls or Misconceptions

• Rucaparib is not approved for clinical or diagnostic applications; research use only [product_spec, source].
• Solubility in ethanol or water is negligible; DMSO is the recommended solvent for stock preparation [product_spec, source].
• Long-term storage (>1 month) of stock solutions is not advised due to potential degradation [workflow_recommendation].
• Transporter-mediated efflux (e.g., ABCB1/Abcb1) may reduce cellular uptake and activity in certain models [paper, DOI].
• Rucaparib does not directly induce apoptosis in all cell types; context-dependent effects depend on DNA repair status [paper, DOI].

Workflow Integration & Parameters

Protocol Parameters

• assay: PARP1 inhibition | value: Ki = 1.4 nM | applicability: in vitro enzymatic assays | rationale: nanomolar affinity supports high potency | source_type: product_spec [link]
• assay: Stock solution preparation | value: ≥10 mM in DMSO, warm and sonicate if needed | applicability: compound handling for cell-based and enzymatic assays | rationale: maximizes solubility and stability for experimental dosing | source_type: workflow_recommendation
• assay: Storage | value: -20°C, avoid long-term storage | applicability: stock compound management | rationale: preserves compound integrity; degradation risk with prolonged storage | source_type: product_spec [link]
• assay: Cell-based radiosensitization | value: 0.01–10 μM, 24–72 h | applicability: DNA damage response in PTEN-deficient/ETS fusion models | rationale: effective concentration window from published studies | source_type: paper [DOI]
• assay: Transporter sensitivity | value: ABCB1/Abcb1 substrate | applicability: models with high efflux transporter expression | rationale: impacts intracellular accumulation and efficacy | source_type: paper [DOI]

Conclusion & Outlook

Rucaparib (AG-014699, PF-01367338) is a cornerstone tool for dissecting DNA repair mechanisms and radiosensitization in cancer research. Its well-defined potency, transporter interactions, and protocol parameters support reproducible, high-sensitivity studies in base excision repair and NHEJ inhibition. As validated by both product specification and recent mechanistic studies, Rucaparib enables researchers to interrogate synthetic lethality and DNA repair vulnerabilities in defined genetic backgrounds [product_spec, source; paper, DOI]. APExBIO continues to support advanced DNA damage response research by providing rigorously characterized reagents. For further exploration of mitochondrial apoptosis and translational perspectives, see "Rucaparib (AG-014699): Elevating Translational Cancer Research", which is complemented here by detailed evidence for transporter effects and protocol optimization.